Physician profile
Albert Dekker
NPI 1578553590
$37,723.95
in general payments reported to CMS, 2019-2025
56 companies · $9,326 in 2025
The $9,326 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,903 · 2020: $8,013 · 2021: $8,299 · 2022: $1,621 · 2023: $3,343 · 2024: $4,219 · 2025: $9,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $4,032 · Long Term Medical Supply Or Device Loan: $167 · Education: $25.95 · Travel and Lodging: $24.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,639.25 |
| Food and Beverage | $4,031.77 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $25.95 |
| Travel and Lodging | $24.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,931.04 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| Acceleron Pharma, INC. | $4,495.00 | 2020 | |
| Genzyme Corporation | $3,211.03 | 2019-2024 | |
| Glaxosmithkline, LLC. | $3,098.77 | 2020-2025 | Ojjaara, Zejula |
| Janssen Biotech, INC. | $2,931.75 | 2019-2025 | Tecvayli, Darzalex, Carvykti |
| Kite Pharma, INC. | $1,801.28 | 2020-2024 | Yescarta |
| Novartis Pharmaceuticals Corporation | $1,766.61 | 2019-2024 | |
| Incyte Corporation | $1,418.39 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Scientific Affairs, LLC | $1,376.25 | 2023-2025 | Tecvayli, Talvey |
| Celgene Corporation | $1,329.86 | 2019-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $1,160.35 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,134.13 | 2019-2025 | Opdivo, Opdualag |
| Seagen INC. | $639.60 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Genentech USA, INC. | $500.97 | 2019-2023 | Phesgo |
| Beigene, LTD. | $450.00 | 2020 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Dekker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.